Karyopharm Therapeutics Inc.

Equities

KPTI

US48576U1060

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
0.9691 ^USD	+2.20%		-7.70%	+12.03%

May. 08	Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Reports Q1 Revenue $33.1M, vs. Street Est of $34.5M	MT
May. 08	Transcript : Karyopharm Therapeutics Inc., Q1 2024 Earnings Call, May 08, 2024

Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Fiscal Year 2022

November 03, 2022 at 04:11 pm EDT

Karyopharm Therapeutics Inc. provided earnings guidance for the fiscal year 2022. For the period, the company expects total revenue to be in the range of $155 million to $165 million. XPOVIO net product revenue to be in the range of $120 million to $130 million.

Latest news about Karyopharm Therapeutics Inc.

Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Reports Q1 Revenue $33.1M, vs. Street Est of $34.5M	May. 08	MT
Transcript : Karyopharm Therapeutics Inc., Q1 2024 Earnings Call, May 08, 2024	May. 08
Karyopharm Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full Year of 2024	May. 08	CI
Karyopharm Therapeutics Inc. announced that it expects to receive $100 million in funding	May. 07	CI
Karyopharm Therapeutics Inc. Announces Presentations in Endometrial Cancer and Myelofibrosis At the 2024 American Society of Clinical Oncology Annual Meeting	Apr. 24	CI
Transcript : Karyopharm Therapeutics Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:00 AM	Mar. 13
Transcript : Karyopharm Therapeutics Inc., Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
Karyopharm Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Posts Q4 Revenue $33.7M, vs. Street Est of $33.6M	Feb. 29	MT
Karyopharm Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Year 2024	Feb. 29	CI
North American Morning Briefing : Fed's Preferred -2-	Feb. 29	DJ
North American Morning Briefing : Stock Futures -2-	Feb. 21	DJ
Transcript : Karyopharm Therapeutics Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 02:15 PM	Jan. 10
Karyopharm Therapeutics Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year 2023	Jan. 08	CI
Karyopharm Therapeutics Inc.(NasdaqGS:KPTI) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Karyopharm Therapeutics Says Phase 1 Study of Myelofibrosis Treatment Showed Spleen Volume Reduction Durability	Dec. 11	MT
Karyopharm Therapeutics Inc. Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi-Naive Myelofib) Patients	Dec. 10	CI
Karyopharm Therapeutics Inc. Announces Resignation of Peter K Honig as Member of the Board of Directors	Dec. 08	CI
RBC Cuts Price Target on Karyopharm Therapeutics to $3 From $4, Keeps Outperform Rating	Nov. 03	MT
Wedbush Trims Karyopharm Therapeutics' PT to $3 From $4, Sees Limited Upside Near Term; Maintains Neutral Rating	Nov. 03	MT
Karyopharm Therapeutics Inc. Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition	Nov. 02	CI
Transcript : Karyopharm Therapeutics Inc., Q3 2023 Earnings Call, Nov 02, 2023	Nov. 02
Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Posts Q3 Revenue $36M, vs. Street Est of $37.4M	Nov. 02	MT

Chart Karyopharm Therapeutics Inc.

Duration

Period

More charts

Company Profile

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Companyâs product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.

Sector

Biotechnology & Medical Research

Calendar

01:30pm - American Society of Clinical Oncology Meeting - Abstract No:427956

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Karyopharm Therapeutics Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.9691 USD

Average target price

5.214 USD

Spread / Average Target

+438.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
KARYOPHARM THERAPEUTICS INC.	+12.03%	121M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs